Bisphosphonate-Related Osteonecrosis in a Patient with Florid Cemento-Osseous Dysplasia

  • Seo, Dong-Jun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • Moon, Seong-Yong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • You, Jae-Seek (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • Oh, Ji-Su (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University)
  • Received : 2021.03.17
  • Accepted : 2021.04.01
  • Published : 2021.06.30


Florid cemento-osseous dysplasia (FCOD) is benign, non-neoplastic lesion characterized by multiple sclerosing masses. Cases of bisphosphonate-related osteonecrosis in FCOD have been rarely reported. we present the patient had multiple osteonecrosis with FCOD in the jaw that occurred after receiving bisphosphonates for eight years due to osteoporosis This report discussed the importance of evaluation of the bone disease in the jaw before bisphosphonate treatment and periodic follow-up.


  1. de Noronha Santos Netto J, Machado Cerri J, Miranda AM, Pires FR. Benign fibro-osseous lesions: clinicopathologic features from 143 cases diagnosed in an oral diagnosis setting. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:e56-e65.
  2. Coleman H, Altini M, Kieser J, Nissenbaum M. Familial florid cemento-osseous dysplasia--a case report and review of the literature. J Dent Assoc S Afr 1996;51:766-770.
  3. El-Mofty SK, Nelson B, Toyosawa S, Wright JM. Cemento-osseous dysplasia. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. WHO classification of head and neck tumours. 4th ed. Lyon: IARC Press; 2017. pp. 254-255.
  4. Mangala M, Ramesh DN, Surekha PS, Santosh P. Florid cementoosseous dysplasia: review and report of two cases. Indian J Dent Res 2006;17:131-134.
  5. Ong ST, Siar CH. Florid cemento-osseous dysplasia in a young Chinese man. Case report. Aust Dent J 1997;42:404-408.
  6. Melrose RJ, Abrams AM, Mills BG. Florid osseous dysplasia. A clinical-pathologic study of thirty-four cases. Oral Surg Oral Med Oral Pathol 1976;41:62-82.
  7. Fenerty S, Shaw W, Verma R, et al. Florid cemento-osseous dysplasia: review of an uncommon fibro-osseous lesion of the jaw with important clinical implications. Skeletal Radiol 2017;46:581-590.
  8. Beylouni I, Farge P, Mazoyer JF, Coudert JL. Florid cementoosseous dysplasia: report of a case documented with computed tomography and 3D imaging. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:707-711.
  9. Waldron CA. Fibro-osseous lesions of the jaws. J Oral Maxillofac Surg 1993;51:828-835.
  10. Cavalcante MB, de Oliveira Lima AL, Junior MA, Santos MB. Florid cemento-osseous dysplasia simultaneous the chronic suppurative osteomyelitis in mandible. J Craniofac Surg 2016;27: 2173-2176.
  11. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
  12. Senel FC, Saracoglu Tekin U, Durmus A, Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogencontaining bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007;65:562-565.
  13. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
  14. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-1956.
  15. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
  16. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018;69:177-187.